{"analyses":[{"ciLowerLimit":"0.23","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.39","estimateComment":"Hazard ratio was estimated by Cox regression model.","groupDescription":"Stratified Analysis; Stratification factors: 17p deletion, risk status, geographic region.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.30","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.25","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.41","estimateComment":"Hazard ratio was estimated by Cox regression model.","groupDescription":"Unstratified Analysis","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.32","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.7","upperLimit":"29.5","value":"24.0"},{"groupId":"OG001","lowerLimit":"56.1","upperLimit":"73.6","value":"63.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"194"}],"units":"Participants"}],"description":"TTNT was defined as the time from randomization until start of new non-protocol-specified anti-CLL treatment or death from any cause. Participants without the event at the time of analysis were censored at the last visit date for this outcome measure analysis. The median TTNT was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received bendamustine at a dose of 70 milligrams per meter square (mg/m\\^2) via intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for 6 cycles, in combination with rituximab at a dose of 375 mg/m\\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\\^2 on Day 1 of Cycles 2-6.","id":"OG000","title":"Bendamustine + Rituximab Main Study"},{"description":"Participants were initially placed on a venetoclax ramp-up period of 5 weeks and received an initial dose of 20 mg via tablet orally once daily (QD) for initial 1 to 7 days, then venetoclax dose was incremented weekly up to a maximum dose of 400 mg, orally, QD. Participants continued receiving venetoclax at a dose of 400 mg, orally, QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to PD or 2 years, whichever occurred first, as directed by the investigator, in combination with rituximab at a dose of 375 mg/m\\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\\^2 on Day 1 of Cycles 2-6.","id":"OG001","title":"Venetoclax + Rituximab Main Study"}],"paramType":"MEDIAN","populationDescription":"ITT population included all randomized participants, with participants grouped according to randomized treatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"Baseline up to start of new ani-CLL therapy or death, whichever occurred first (up to approximately 8 years 5 months)","title":"Time to New Anti-CLL Treatment (TTNT) as Assessed by the Investigator","type":"SECONDARY","unitOfMeasure":"months"}